Interim report January – July 2010
Good growth in sales and profitability with continuous concentration on strategic investments.
Period January – June
- Growth in local currency was 14 percent. Sales amounted to SEK 149 (142) million, corresponding to an increase of 5 percent in SEK.
- Operating income before research and development costs increased by 14 percent and amounted to SEK 41 (36) million.
- Operating income (EBIT) increased by 13 percent and amounted to SEK 19 (17) million. The operating margin was 13 (12) percent.
- The Group’s net income amounted to SEK 19 (16) million.
Quarter in brief
- Growth in local currency was 13 percent. Sales amounted to SEK 73 (70) million, corresponding to an increase of 4 percent in SEK.
- Operating income before research and development costs increased by 7 percent and amounted to SEK 20 (19) million.
- Operating income (EBIT) increased by 11 percent and amounted to SEK 9 (8) million. The operating margin was 12 (11) percent.
- The Group’s net income amounted to SEK 9 (7) million, which gives earnings per share of SEK 0.48 (0.38).
- The cash flow from operating activities was SEK 13 (12).
- Dividend paid by 0.50 SEK per share.
- The clinical study on STEEN Solution™ presented good treatment results.
- Collaboration agreement with University of Melbourne regarding development of stem cell media.
- Collaboration agreement with the Danish company HertART Aps regarding development of fertility products.
- Good clinical results from Swemed Sense™ multicenter study presented.
July 15, 2010
Gothenburg
Magnus Nilsson
CEO
Queries should be addressed to:
Magnus Nilsson, CEO; phone +46 31 721 80 61
Eva Nilsagård, CFO, phone +46 31 721 80 13
________________________________________________________________________________________________________________________________ Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Stem Cell Cultivation. The Fertility product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. The Transplantation product area works with solutions and systems to evaluate and maintain organs outside the body order to select usable organs and keeping them in optimal condition while waiting for transplantation. The Stem Cell Cultivation product area works with media and instruments to enable the use and handling of stem cells for therapeutic purposes. Vitrolife today has approximately 180 employees and the company’s products are sold in more than 85 markets. The company is headquartered in Gothenburg, Sweden, and there are subsidiaries in USA, Australia, France, Italy and Japan. Production facilities are located in Sweden and USA. The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap. _________________________________________________________________________________________________________________________________ Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolife.com. Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on Thursday July 15, 2010 at 08:30 am CET. This is a translation of the Swedish version of the notice. When in doubt, the Swedish wording prevails.
